Clinical Diagnosis Guidelines for Transthyretin Amyloidosis | oneAMYLOIDOSISvoice
×
Or register here
Global Search

Trusted Resources: Education

Scientific literature and patient education texts

Back to Education / Patient Education

Clinical Diagnosis Guidelines for Transthyretin Amyloidosis

key information

source: Institute for Patient Access

year: 2020

summary/abstract:

Amyloidosis is a rare disease caused by a buildup of abnormal proteins in the body’s organs and tissue. Diagnosing amyloidosis can be difficult because symptoms often seem unrelated. In fact, an amyloidosis diagnosis is generally delayed three to four years. The disease is also frequently misdiagnosed. Delayed diagnosis or misdiagnosis means delayed treatment, allowing amyloidosis to progress and increasing the risk of premature death for patients.
 
Recent guidelines reflect global consensus on the clues that lead to a diagnosis of transthyretin amyloidosis, a specific type of the disease. This form of amyloidosis can be hereditary, where a genetic mutation spans multiple generations, or spontaneous, where no genetic mutation exists. 
 
Guidelines simplify disease patterns and highlight commonly affected populations. By bridging the gap between the onset of symptoms and the beginning of treatment, the guidelines can help to improve patients’ quality of life and slow disease progression as early as possible.
 
read more

Related Content

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close

Community Key Collaborator

Support for this landing page is provided by an independent education grant from

Translation of this platform made possible through an independent education grant from

© 2025 rareLife solutions Inc.

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close